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a b s t r a c t
We present a short case series of elderly patients with NK-AML and isolated NPM1 mutation who were
treated with intensive chemotherapy, achieving signiﬁcant CRs multiple times on reinduction, even with
a single course.We hope to highlight the NPM1 as a molecular marker in elderly for consideration of
aggressive treatment, even if abridged, as this subset may achieve a durable, good quality responses at
diagnosis or subsequent relapses.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
We report our experience in treating elderly but ﬁt individuals
with AML and NPM1mutation. Wewould particularly like to highlight
the ability to re-induce remission repeatedly on subsequent relapses
with the possibility of achieving a durable response with only a single
course of re-induction treatment. Older AML patients who relapse are
generally not offered intensive salvage treatments but we report a
subgroup with clinically meaningful response to such intervention.
We present 3 cases of older patients with AML with isolated
NPM1 mutation treated repeatedly with intensive chemotherapy.
Case 1 was a 75-year-old female diagnosed with normal kar-
yotype (NK) AML with isolated NPM1 mutation on a background of
longstanding chronic neutropenia. She was treated with intensive
therapy in the NCRI AML16 clinical trial (Table 1). She had a
morphological CR1 for around 16 months. First relapse was success-
fully treated with a single course of intensive relapse treatment
(Table 1) to achieve a dysplastic CR2 for 12 months. At 2nd relapse,
she had acquired FLT3 ITD in addition to NPM1 mutation but
achieved CR3i for 10 months and a CR4 lasting for 10 months with
single courses of intensive treatments (Table 1). Unfortunately, she
died during re-induction at 4th relapse with an encephalopathic
illness and cavitating pulmonary infection.
Case 2 was a 70-year-old male with relapsed NK-AML, and NPM1
mutation identiﬁed at ﬁrst relapse. He was originally treated for NK
AML (FAB-M6) in NCRI AML14 (Table 1)and achieved CR1 for 7 years.
Diagnostic samples at initial presentation were not available to
conﬁrm the NPM1 status but we feel this episode was unlikely to
be therapy related since t-AML with isolated NPM1 is rare and
we can reasonably assume NPM1 mutation at diagnosis given that
NPM1 is normally stable at relapse. He received re-induction with
two courses of ADEþATRA (Table 1) and achieved CR2i (with mild
thrombocytopenia) of 16 months duration. Simultaneous with his
2nd relapse (molecularly stable) he was also diagnosed with locally
advanced prostate carcinoma. He received one re-induction course
of FLAG chemotherapy as this was complicated by prolonged
hospitalisation for sepsis and cachexia and had a CR3 duration of
7 months.The 3rd relapse was treated successfully into CR4 again
with a single course of FLAG but lasted 4 months. The patient was
deemed unsuitable for further re-induction at 4th relapse.
Case 3 was a 69-year-old ﬁt man with NK-AML and isolated
NPM1 mutation treated in the NCRI AML 16 trial (Table 1). CR1
duration was 18 months with self-reported very good QoL. At ﬁrst
relapse (molecularly stable) he was re-induced with 1 course of ADE
(10þ3þ5) followed by 2 courses of consolidation with cytarabine
[3 gm/m2]. CR2 was maintained for 39 months until a 3rdrelapse,
which was successfully treated with a single course of FLAG. He
developed locally advanced carcinoma prostate, treated with hor-
mone manipulation in CR2. His CR3 is ongoing for over 12 months.
Case 1 and 2 had four relapses with an OS of 5 years and 11 years
from the ﬁrst diagnosis of AML. Three relapses were successfully
managed to achieve remission and it is worth noting that Case
1 achieved this thrice and case 2 twice with a single course of
intensive re-induction. The average CR duration was 11.5 months
and 22.75 months respectively. Both had a very good self-reported
quality of life (QoL) in between relapses. Case 3 had a signiﬁcant CR2
for over 3 years and responded well to reinduction with a single
course of FLAG and remains in CR3, with a very good self-reported
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QoL. Even the emergence of FLT3 ITD (which was always assessed for
all the patients at each relapse) in case 1 did not induce chemoresis-
tance with a further 20 months of CR achieved beyond the acquisition
of FLT3 ITD.
Limitations in our cases series include:
(1) The lack of NPM1 mutation analysis at all relapses as it was not
local protocol but when tested on subsequent relapses, NPM1
has been found to be mutated on multiple occasions, implying
that it was likely to be the same clone.We have information
regarding the NPM1 mutation status at various time points for
each patient as demonstrated in Table 2.
(2) Lack of objective assessment of QoL, which is because of the
retrospective nature of case compilation.
The role of intensive treatment is established only in selected
elderly AML patients [1–3] and only a minority of such patients
would be deemed suitable, mostly due to constraints from poor
chemotherapy tolerance in view of age and comorbid illnesses.
NPM1 mutation is present in a similar proportion of younger
and elderly (460 years) AML patients (52.1 vs. 66.4% of NK AML)
[4]. It is an independent predictor of better survival and longer
duration of remission in multivariate analyses when the FLT3 was
wild type at diagnosis [4,5]. A multivariate analysis in AML-NK
patients Z70 years found NPM1 mutation as the sole indepen-
dent parameter inﬂuencing prognosis [6].
It has been proven that NPM1 mutated AMLs are highly
responsive to chemotherapy in patients under 60 years [7–10].
In Z60 years with NPM1 mutation, following treatment with
intensive protocols, CR rates were higher (84% vs. 48%) and the
relapse free survival (23% vs. 10% at 3 years) and OS (35% vs. 8% at
3 years) were better [6] in comparison to unmutated NPM1. The
independent prognostic impact was most pronounced in Z70
years [6]. Intensive treatment of the ﬁt octogenarian population
also results in signiﬁcantly longer overall survival in patients with
NPM1 mutation as a sole abnormality while FLT3 ITD did not have
any effect [11]. These studies suggest that NPM1 mutation may be
used as a molecular marker in elderly patients for consideration of
aggressive treatment.
Thus, wewish to reiterate the favourable impact of NPM1mutation
on prognosis and chemosensitivity in elderly patients, and to draw
attention to the following:
(a) This subset of AML patients may attain a durable, good quality
response with a single cycle of intensive therapy
(b) They could be successfully re-induced multiple times, if ﬁt and
suitable for intensive treatment.
It does appear that the maximum beneﬁt is seen with the ﬁrst
treatment and duration of CR is shortened in subsequent relapses.
This may be secondary to the (i) abridged chemotherapy protocols
(single course), (ii) development of comorbidities and impact
of previous chemotherapies and (most likely) (iii) the evolution
of disease with resistant sub-clones. Younger ﬁtter patients will of
course be candidates for allograft but our cases were not con-
sidered eligible due to age and/or co-morbidities.
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Table 1
Summary of the cases-elderly AML with NPM1 mutation as sole abnormality.
Case 1 Case 2 Case 3
Age at diagnosis 75 years female 63 years male 69 year male
Comorbid illnesses None none Frozen shoulder
Induction treatment DA 3þ10, 3þ8, 2þ5 DAT 3þ10, 3þ8 – MIDAC DCLoþ1 course of Mylotarg
As per AML16 trial 1 cycle of azacitidine maintenance ICE 2þ3 As per AML16
Duration of CR1 16(18 if include 2 months of observation) months 100 months 18 months
2nd treatment ADEþATRA ADEþATRA ADEþ intermediate dose Ara C
1 course 2 courses
Duration of CR2 12 months 18 months 39 months
3rd treatment FLAG FLAG FLAG
Duration of CR3 10 months 7 months Ongoing
Treatment Mercaptopurine ADE FLAG
Duration of CR4 10 months 7 months
Cause of death Died in 4th relapse Died in 4th relapse NA
OS from diagnosis 5 years 11 years Alive in CR3
Total relapses 4 4 2
Average CR duration 11.5 months 27.75 months 28.5 months
DA DaunorubicinþCytarabine
DClo DaunorubicinþClofarabine
ADE DaunorubicinþCytarabineþEtoposide(ADE)
MIDAC Modiﬁed Intermediate-Dose Cytarabine
FLAG Fludarabine, Cytarabine, GCSF
ICE Idarubicin , high-dose Cytarabine (HiDAC), Etoposide
Table 2
Summary of the NPM1 mutation status at various time points.
Case 1 Case 2 Case 3
Diagnosis Mutated Not known Mutated
CR1 Not known Not known Not known
1st relapse mutated Mutated Not known
CR2 Not known Not known Not known
2nd relapse Failed npm1 but ﬂt3þ Not known Mutated
CR3 Mutated Not known Not known
3rd relapse Mutated Mutated Not applicable
CR4 Not known Not known Not applicable
4th relapse Mutated Not known Not applicable
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